Relief Hldg Stock Price, News & Analysis

Relief Therapeutics Holding SA has filed Amendment No. 2 to its Registration Statement on Form F-1 with the SEC, proposing an offering of up to 833,333,200 ordinary shares as American Depositary Shares (ADSs). The preliminary prospectus includes warrants for an additional 625,000,000 shares. Underwriters may also purchase an extra 125,000,000 shares and warrants. The terms of the offering remain uncertain, pending finalization in a future amendment. The effectiveness of the registration statement and completion of the offering are not guaranteed, affecting potential investor interest.

Relief Therapeutics and NRx Pharmaceuticals have finalized settlement agreements resolving litigation between them. Key outcomes include Relief acquiring all assets related to the aviptadil development program, including regulatory filings and clinical data. Relief will now exclusively develop and commercialize aviptadil, continuing its Right to Try Program for two years. Moreover, Relief will make milestone payments to NeuroRx for commercial approval and pay royalties, capped at $30 million. The companies have agreed not to compete in aviptadil development.

Relief Therapeutics Holding SA will present at the 15th Annual Biotech Showcase and host investor meetings on January 9-10, 2023, in San Francisco. CEO Jack Weinstein will provide insights into the company’s rare disease portfolio and commercial strategy. The Biotech Showcase presentation is scheduled for January 10 at 3:30 PM PST. The company focuses on developing novel treatments for rare diseases and holds a diverse pipeline, including products for phenylketonuria and epidermolysis bullosa.

Relief Therapeutics Holding SA has announced an increase in its share capital from 4.62 billion to 5.62 billion shares by issuing 1 billion new shares, fully subscribed by its subsidiary, Relief Therapeutics International SA. These new shares will be listed on the SIX Swiss Exchange around December 22, 2022. Following this issuance, Relief expects about 1.2 billion shares to be held in treasury for future financing transactions, while the outstanding shares will remain unchanged until placement.

Relief Therapeutics announces leadership changes with Jack Weinstein appointed as CEO and Jeremy Meinen as CFO. Effective immediately, Weinstein aims to enhance the company's long-term strategy following the launch of their first product, PKU GOLIKE. Meinen, who has been with Relief since 2020, now takes on more responsibility in driving financial growth. These appointments come after the settlement of litigation with NRx Pharmaceuticals, signaling a strategic shift for Relief to focus on expanding its operations in the biopharmaceutical sector.

Relief Therapeutics announced the filing of Amendment No. 1 to its Registration Statement on Form F-1 with the U.S. SEC for a proposed offering of ordinary shares in the form of American Depositary Shares (ADSs). Details regarding the number and pricing of the ADSs are yet to be determined. The company plans to list these ADSs on the NASDAQ under the symbol RLFT. The offering will only proceed with an effective prospectus.

Relief Therapeutics Holding SA and NRx Pharmaceuticals have reached settlement agreements to resolve litigation. Within the next 30 days, NRx will transfer assets used in aviptadil development to Relief. Relief will gain exclusive rights to develop and commercialize aviptadil while continuing the Right to Try Program for two years. They will pay NRx milestone payments for successful product approvals and royalties up to $30 million based on sales. NRx will refrain from future competition in aviptadil development. The success of aviptadil commercialization is uncertain.

Relief Therapeutics Holding SA and NRx Pharmaceuticals, Inc. have extended the stay of their pending litigation until November 11, 2022. They are progressing in negotiations for a settlement; however, no final agreements have been reached, introducing uncertainty about the outcome.

Relief specializes in developing treatments for rare diseases, with products including PKU GOLIKE and ongoing projects like aviptadil and APR-TD011, which has FDA Orphan Drug Designation. The company is listed on the SIX Swiss Exchange under symbol RLF and OTCQB under RLFTF and RLFTD.

Relief Therapeutics, a Swiss biopharmaceutical company, has announced promising six-month stability data for a new formulation of RLF-100 (aviptadil) that shows high purity across various temperatures. This data supports the commercialization of RLF-100, which targets serious lung diseases like pulmonary sarcoidosis and ARDS. Relief plans to initiate a Phase 2b study in 2023 for pulmonary sarcoidosis. The company has also filed a provisional patent application for this formulation, underlining its potential clinical and commercial value.